← Back to patent-cliff list
Danifexor
Tier C — Watch / tradeDanifexor
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FXR
Indications (approved)：胆管炎, Sclerosing cholangitis, Chronic hepatitis B, Non-alcoholic steatohepatitis
Regional status
US
Phase I
2020-11-30
EU
-
China
Phase II
2022-01-10
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Danifexor?
Approved indications include: 胆管炎, Sclerosing cholangitis, Chronic hepatitis B, Non-alcoholic steatohepatitis.
When does the Danifexor patent expire?
No public expiry year is available for Danifexor yet; this page updates once verified.
How do I get a quote for Danifexor intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05